UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Growth Hormone-Releasing Hormone (GHRH) Antagonists Inhibit the Proliferation of Androgen-Dependent and -Independent Prostate Cancers

Proceedings of the National Academy of Sciences - PNAS, 2003-02, Vol.100 (3), p.1250-1255

2003

Volltextzugriff (PDF)

Preclinical Evaluation of Targeted Cytotoxic Luteinizing Hormone-Releasing Hormone Analogue AN-152 in Androgen-Sensitive and Insensitive Prostate Cancers

Clinical cancer research, 2003-10, Vol.9 (12), p.4505-4513

2003

Volltextzugriff (PDF)

Lipopeptide Antagonists of Growth Hormone-Releasing Hormone with Improved Antitumor Activities

Proceedings of the National Academy of Sciences - PNAS, 2006-03, Vol.103 (12), p.4610-4615

2006

Volltextzugriff (PDF)

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers

International journal of cancer, 2006-01, Vol.118 (1), p.222-229

2006

Volltextzugriff (PDF)

Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238

The Journal of urology, 2004-02, Vol.171 (2), p.911-915

2004

Volltextzugriff (PDF)

The Worst Case: Giant Exulcerating Seminoma

Urologia internationalis, 2010-01, Vol.84 (1), p.113-115

2010

Volltextzugriff (PDF)

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

The Prostate, 2002-08, Vol.52 (3), p.173-182

2002

Volltextzugriff (PDF)

Revival of Palaeoptera—head characters support a monophyletic origin of Odonata and Ephemeroptera (Insecta)

Cladistics, 2012-12, Vol.28 (6), p.560-581

2012

Volltextzugriff (PDF)

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

Geburtshilfe und Frauenheilkunde, 2023-08, Vol.83 (8), p.919-962

2023

Volltextzugriff (PDF)

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022) – Part 2 with Recommendations on the Therapy of Precancerous Lesions and Early-stage Endometrial Cancer, Surgical Therapy, Radiotherapy and Drug-based Therapy, Follow-up Care, Recurrence and Metastases, Psycho-oncological Care, Palliative Care, Patient Education, and Rehabilitative and Physiotherapeutic Care

Geburtshilfe und Frauenheilkunde, 2023-08, Vol.83 (8), p.963-995

2023

Volltextzugriff (PDF)

Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project

Journal of cancer research and clinical oncology, 2023-09, Vol.149 (11), p.8829-8842

2023

Volltextzugriff (PDF)

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

Geburtshilfe und Frauenheilkunde, 2023-08, Vol.83 (8), p.919-962

2023

Volltextzugriff (PDF)

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities

Geburtshilfe und Frauenheilkunde, 2018-11, Vol.78 (11), p.1089-1109

2018

Volltextzugriff (PDF)

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

Geburtshilfe und Frauenheilkunde, 2018-10, Vol.78 (10), p.949-971

2018

Volltextzugriff (PDF)

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities

Geburtshilfe und Frauenheilkunde, 2018-11, Vol.78 (11), p.1089-1109

2018

Volltextzugriff (PDF)

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

Geburtshilfe und Frauenheilkunde, 2018-10, Vol.78 (10), p.949-971

2018

Volltextzugriff (PDF)

Vorwort

Klinikleitfaden Hämatologie Onkologie, 2021, p.VI-VI

Second Edition, 2021

Volltextzugriff (PDF)

Adressen

Klinikleitfaden Hämatologie Onkologie, 2021, p.VII-IX

Second Edition, 2021

Volltextzugriff (PDF)

Endpaper

Klinikleitfaden Hämatologie Onkologie, 2021, p.IBC1-IBC3

Second Edition, 2021

Volltextzugriff (PDF)

Abkürzungen

Klinikleitfaden Hämatologie Onkologie, 2021, p.XII-XXIII

Second Edition, 2021

Volltextzugriff (PDF)

Benutzerhinweise

Klinikleitfaden Hämatologie Onkologie, 2021, p.X-X

Second Edition, 2021

Volltextzugriff (PDF)

Register

Klinikleitfaden Hämatologie Onkologie, 2021, p.599-608

Second Edition, 2021

Volltextzugriff (PDF)

Titelblatt

Klinikleitfaden Hämatologie Onkologie, 2021, p.I-III

Second Edition, 2021

Volltextzugriff (PDF)

Vorwort zur 1. Auflage

Klinikleitfaden Hämatologie Onkologie, 2021, p.V-V

Second Edition, 2021

Volltextzugriff (PDF)

Weitere Bücher bei Elsevier

Klinikleitfaden Hämatologie Onkologie, 2021, p.609-612

Second Edition, 2021

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(16)
Buchkapitel
(10)

Sprache

Deutsch
(14)
Englisch
(12)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(9)
Humans
(7)
Male
(7)
Animals
(6)
Mice
(5)
Mice, Nude
(5)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Oncology
(4)
Prostatic Neoplasms - Pathology
(4)
Tumor Cells, Cultured
(4)
Tumors
(4)
Cancer
(3)
Doxorubicin - Analogs & Derivatives
(3)
Gebfra Science
(3)
Obstetrics & Gynecology
(3)
Prostatic Neoplasms - Drug Therapy
(3)
Reverse Transcriptase Polymerase Chain Reaction
(3)
Rna, Messenger - Metabolism
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Growth Hormone-Releasing Hormone (GHRH) Antagonists Inhibit the Proliferation of Androgen-Dependent and -Independent Prostate Cancers

Preclinical Evaluation of Targeted Cytotoxic Luteinizing Hormone-Releasing Hormone Analogue AN-152 in Androgen-Sensitive and Insensitive Prostate Cancers

Lipopeptide Antagonists of Growth Hormone-Releasing Hormone with Improved Antitumor Activities

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers

Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238

The Worst Case: Giant Exulcerating Seminoma

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

Revival of Palaeoptera—head characters support a monophyletic origin of Odonata and Ephemeroptera (Insecta)

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project

Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) – Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer

Vorwort

Adressen

Endpaper

Abkürzungen

Benutzerhinweise

Register

Titelblatt

Vorwort zur 1. Auflage

Weitere Bücher bei Elsevier

Suchergebnisse filtern